HPRL
MCID: HYP020
MIFTS: 64

Hyperprolactinemia (HPRL)

Categories: Blood diseases, Endocrine diseases, Genetic diseases, Metabolic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Hyperprolactinemia

MalaCards integrated aliases for Hyperprolactinemia:

Name: Hyperprolactinemia 56 12 74 73 36 29 54 6 43 15 17 71
Chiari-Frommel Syndrome 12 74 52 43 71
Hyperprolactinaemia 12 32
Hprl 56 73
Familial Isolated Prolactin Receptor Deficiency 58
Pregnancy-Related a-G Syndrome 12
Familial Hyperprolactinemia 58
Hyperprolactinemia, 39

Characteristics:

Orphanet epidemiological data:

58
familial hyperprolactinemia
Inheritance: Autosomal dominant; Age of onset: Adult;

OMIM:

56
Inheritance:
autosomal recessive
autosomal dominant


HPO:

31

Classifications:

Orphanet: 58  
Rare infertility disorders
Rare endocrine diseases


External Ids:

Disease Ontology 12 DOID:12700
OMIM 56 615555
KEGG 36 H01388
NCIt 49 C113168
SNOMED-CT 67 237662005 85039006
ICD10 32 E22.1
ICD10 via Orphanet 33 E22.1
Orphanet 58 ORPHA397685
MedGen 41 C0020514
UMLS 71 C0008043 C0020514

Summaries for Hyperprolactinemia

OMIM : 56 Hyperprolactinemia unrelated to pregnancy occurs in approximately 0.1 to 0.3% of the general population and may result in infertility, hypogonadism, and galactorrhea. Such nonphysiologic hyperprolactinemia is caused mainly by drugs or by tumors in the anterior pituitary gland, primarily prolactinomas (see 102200). However, 10 to 60% of patients with hyperprolactinemia who undergo MRI have normal findings (summary by Newey et al., 2013). Patients with hyperprolactinemia may also experience agalactia (Kobayashi et al., 2018). (615555)

MalaCards based summary : Hyperprolactinemia, also known as chiari-frommel syndrome, is related to galactorrhea and mccune-albright syndrome. An important gene associated with Hyperprolactinemia is PRLR (Prolactin Receptor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and JAK-STAT signaling pathway. The drugs Orlistat and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include pituitary, ovary and bone, and related phenotypes are galactorrhea and oligomenorrhea

Disease Ontology : 12 An acquired metabolic disease that has material basis in the presence of abnormally-high levels of prolactin in the blood.

KEGG : 36 Hyperprolactinemia unrelated to pregnancy is a disorder characterized by excess production of prolactin (PRL) and may result in infertility, hypogonadism, and galactorrhea. Such nonphysiological hyperprolactinemia is caused mainly by drugs or by tumors in the anterior pituitary gland, which are usually identifiable by means of magnetic resonance imaging (MRI). Some cases are due to prolactinomas and lesions in the pituitary stalk. A human germline PRLR mutation has been found in familial isolated hyperprolactinemia.

UniProtKB/Swiss-Prot : 73 Hyperprolactinemia: A disorder characterized by increased levels of prolactin in the blood not associated with gestation or the puerperium. HPRL may result in infertility, hypogonadism, and galactorrhea.

Wikipedia : 74 Hyperprolactinaemia is the presence of abnormally high levels of prolactin in the blood. Normal levels... more...

Related Diseases for Hyperprolactinemia

Diseases related to Hyperprolactinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 585)
# Related Disease Score Top Affiliating Genes
1 galactorrhea 33.3 PRLR PRL IGF1 DRD2
2 mccune-albright syndrome 32.3 SST PTHLH PRL IGF1 GNAS GH1
3 hypogonadotropic hypogonadism 32.3 SHBG PRL INS GNRH1
4 pituitary tumors 31.1 SST PRL POMC IGF1 GNAS GH1
5 precocious puberty 31.0 GNRH1 GNAS GH1
6 diabetes insipidus 30.8 PRL POMC INS GH1
7 thyroiditis 30.7 TRH PRL INS
8 hypogonadism 30.7 SHBG PRL INS IGF1 GNRH1
9 amenorrhea 30.7 TRH SHBG PRL POMC INS IGF1
10 non-functioning pituitary adenoma 30.6 SST GH1
11 gynecomastia 30.6 SHBG PRL POMC GNRH1 DRD2
12 gigantism 30.5 PRL GHRH GH1
13 adenoma 30.5 TRH SST PRL POMC IGF1 GNAS
14 chromophobe adenoma 30.5 TRH PRLR PRL POMC GH1
15 central precocious puberty 30.4 IGF1 GNRH1 GH1
16 abducens nerve disease 30.4 PRL POMC
17 tsh producing pituitary tumor 30.4 SST PRL GH1
18 intracranial hypertension, idiopathic 30.4 POMC IGF1 GH1
19 impotence 30.3 VIP SHBG PRL POMC INS GNRH1
20 tic disorder 30.3 HTR2A DRD4 DRD2
21 sheehan syndrome 30.3 PRL POMC INS IGF1
22 lymphocytic hypophysitis 30.3 POMC GH1
23 anovulation 30.3 SHBG PRL INS IGF1 GNRH1 DRD2
24 craniopharyngioma 30.3 TRH PRL INS IGF1 GNRH1 GH1
25 secondary adrenal insufficiency 30.3 INS IGF1
26 premenstrual tension 30.3 SHBG POMC GNRH1
27 bone resorption disease 30.3 PTHLH INS IGF1
28 chiasmal syndrome 30.2 SST POMC
29 acth deficiency, isolated 30.2 TRH PRL POMC
30 ovarian cyst 30.2 PRL GNRH1 GNAS
31 empty sella syndrome 30.2 TRH PRL POMC INS IGF1 GNRH1
32 meningioma, familial 30.2 SST PRL POMC IGF1
33 infertility 30.2 SHBG PRLR PRL H19 GNRH1
34 psychotic disorder 30.1 PRL HTR2C HTR2A DRD4 DRD2
35 leydig cell tumor 30.1 PTHLH GNRH1 GNAS
36 acth-secreting pituitary adenoma 30.1 SST PRL POMC
37 adrenal adenoma 30.0 POMC INS GNAS
38 migraine without aura 30.0 PRL DRD4 DRD2
39 parathyroid adenoma 30.0 PTHLH IGF1 GNAS
40 fasting hypoglycemia 30.0 POMC IGF1
41 polycystic ovary syndrome 30.0 SHBG PRL POMC INS IGF1 GNRH1
42 tuberous sclerosis 30.0 SST POMC INS IGF1
43 pituitary adenoma 1, multiple types 30.0 SST PRL IGF1 GH1
44 fibromyalgia 29.9 PRL POMC IGF1 HTR2A DRD2
45 estrogen excess 29.8 SHBG PRL GNRH1
46 gastroparesis 29.8 SST PRL DRD4 DRD2
47 glucose intolerance 29.8 SHBG POMC INS IGF1 GH1
48 pituitary adenoma, prolactin-secreting 29.8 TRH SST PTHLH PRL POMC IGF1
49 schizophreniform disorder 29.8 PRL HTR2A DRD4 DRD2
50 hypoglycemia 29.8 SST PRL POMC INS IGF1 GHRH

Graphical network of the top 20 diseases related to Hyperprolactinemia:



Diseases related to Hyperprolactinemia

Symptoms & Phenotypes for Hyperprolactinemia

Human phenotypes related to Hyperprolactinemia:

58 31 (show all 11)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 galactorrhea 58 31 occasional (7.5%) Very frequent (99-80%) HP:0100829
2 oligomenorrhea 58 31 occasional (7.5%) Very frequent (99-80%) HP:0000876
3 infertility 58 31 occasional (7.5%) Frequent (79-30%) HP:0000789
4 amenorrhea 58 31 frequent (33%) Frequent (79-30%) HP:0000141
5 hemorrhagic ovarian cyst 58 31 frequent (33%) Frequent (79-30%) HP:0012886
6 osteopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000938
7 osteoporosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000939
8 menorrhagia 58 31 occasional (7.5%) Occasional (29-5%) HP:0000132
9 female hypogonadism 58 31 occasional (7.5%) Occasional (29-5%) HP:0000134
10 agalactia 31 very rare (1%) HP:0031109
11 increased circulating prolactin concentration 31 HP:0000870

Symptoms via clinical synopsis from OMIM:

56
Genitourinary Internal Genitalia Female:
infertility (in some patients)
oligomenorrhea (in some patients)
menorrhagia (in some patients)

Chest Breasts:
galactorrhea (in some patients)
agalactia (in some patients)

Endocrine Features:
elevated prolactin levels

Clinical features from OMIM:

615555

MGI Mouse Phenotypes related to Hyperprolactinemia:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 DRD2 DRD4 GAL GHRH GNAS HTR2A
2 homeostasis/metabolism MP:0005376 10.36 DRD2 DRD4 GAL GHRH GNAS GNRH1
3 endocrine/exocrine gland MP:0005379 10.34 DRD2 GAL GHRH GNAS GNRH1 HTR2A
4 growth/size/body region MP:0005378 10.29 DRD2 GAL GHRH GNAS GNRH1 HTR2C
5 immune system MP:0005387 10.21 DRD2 GHRH GNAS GNRH1 HTR2C IGF1
6 adipose tissue MP:0005375 10.18 DRD2 GHRH GNAS HTR2C IGF1 INS
7 integument MP:0010771 10.14 DRD2 GAL GNAS GNRH1 HTR2C IGF1
8 nervous system MP:0003631 10.13 DRD2 DRD4 GAL GHRH GNAS GNRH1
9 liver/biliary system MP:0005370 9.97 DRD2 GHRH GNAS GNRH1 INS POMC
10 neoplasm MP:0002006 9.92 DRD2 GNAS GNRH1 IGF1 POMC PRL
11 renal/urinary system MP:0005367 9.76 DRD2 GNAS GNRH1 IGF1 INS POMC
12 reproductive system MP:0005389 9.65 DRD2 GAL GHRH GNRH1 IGF1 INS
13 skeleton MP:0005390 9.36 DRD2 GHRH GNAS GNRH1 HTR2A IGF1

Drugs & Therapeutics for Hyperprolactinemia

Drugs for Hyperprolactinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
2
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
3
Quinagolide Approved, Investigational Phase 4 87056-78-8, 97805-50-0 105105
4
Ziprasidone Approved Phase 4 146939-27-7 60854
5
Clozapine Approved Phase 4 5786-21-0 2818
6
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
7
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
8
Amantadine Approved Phase 4 768-94-5 2130
9
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
10
Polyestradiol phosphate Approved Phase 4 28014-46-2
11
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
12
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
13 Insulin, Globin Zinc Phase 4
14 insulin Phase 4
15 Anti-Obesity Agents Phase 4
16 Lipid Regulating Agents Phase 4
17 Appetite Depressants Phase 4
18 Dopamine agonists Phase 4
19 Serotonin 5-HT1 Receptor Agonists Phase 4
20 Serotonin Receptor Agonists Phase 4
21 Trace Elements Phase 4
22 Micronutrients Phase 4
23 Vitamins Phase 4
24 Nutrients Phase 4
25 Calciferol Phase 4
26 Calcium, Dietary Phase 4
27 Mitogens Phase 4
28 Endothelial Growth Factors Phase 4
29 Paliperidone Palmitate Phase 4
30 Angiogenesis Inducing Agents Phase 4
31 Antipsychotic Agents Phase 4
32 Dopamine Agents Phase 4
33 Dopamine Antagonists Phase 4
34 Antidepressive Agents Phase 4
35 Psychotropic Drugs Phase 4
36 Hormones Phase 4
37 Antiparkinson Agents Phase 4
38 Anti-Infective Agents Phase 4
39 Analgesics, Non-Narcotic Phase 4
40 Antiviral Agents Phase 4
41 Quetiapine Fumarate Phase 4 111974-72-2
42 Estradiol 17 beta-cypionate Phase 4
43 Estradiol 3-benzoate Phase 4
44
Calcium Nutraceutical Phase 4 7440-70-2 271
45
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
46
Bromocriptine Approved, Investigational Phase 3 25614-03-3 31101
47
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
48
Metformin Approved Phase 3 657-24-9 14219 4091
49
Cyproterone Acetate Approved, Investigational Phase 2, Phase 3 427-51-0
50
Lactitol Approved, Investigational Phase 3 585-88-6, 585-86-4 493591

Interventional clinical trials:

(show top 50) (show all 92)
# Name Status NCT ID Phase Drugs
1 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
2 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
3 The Effect of Weight Loss With Orlistat or Sibutramine Administration , Hypocaloric Diet and Physical Exercise , on AMH Levels, in Women With Polycystic Ovary Syndrome Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
4 Aripiprazole Treatment for Antipsychotic Induced Hyperprolactinaemia in Patients With Severe Mental Illness and Learning Disabilities Completed NCT01085383 Phase 4 Aripiprazole
5 Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions. Completed NCT00625950 Phase 4
6 Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients Completed NCT01957839 Phase 4 cabergoline treatment
7 Open-Label Study of Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Spectrum Disorder Completed NCT00181922 Phase 4 ziprasidone (Geodon)
8 Open Label Trial of Aripiprazole in the Treatment of CD in Adolescents Completed NCT00250705 Phase 4 Aripiprazole
9 Augmentation of Clozapine With Paliperidone in the Treatment of Resistant Schizophrenia Randomized Controlled Study Completed NCT01279213 Phase 4 paliperidone clozapine
10 Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs Completed NCT01050582 Phase 4 Risperidone;Other atypical antipsychotic drugs
11 The Effects of Vitamin D Supplementation on Transforming Growth Factor-beta1 and Vascular Endothelial Growth Factor in Vitamin D-Deficient Women With Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Trial Completed NCT02460380 Phase 4 Vitamin D3
12 Risperidone Augmentation in Patients With Schizophrenia Partially Responsive to Clozapine Completed NCT00289861 Phase 4 Risperidone;placebo
13 Amantadine Addition to Paliperidone ER or Risperidone Consta Therapy for Prolactin Elevation Terminated NCT00975611 Phase 4 Amantadine Hydrochloride, USP;Amantadine Hydrochloride, USP;Placebo
14 Randomized, Open Label, 8-Week Study of Quetiapine and Risperidone on Quality of Life in Female With Schizophrenia Terminated NCT00498004 Phase 4 Quetiapine, Risperidone
15 The Luveris® In Vitro Fertilization Trial: The Effect of Recombinant Luteinizing Hormone on Follicular Response, Oocyte Quality, and Pregnancy in In-Vitro Fertilization Treatment Cycles in Women Without Endogenous LH Activity. Terminated NCT00889512 Phase 4 Luveris fixed dose;Luveris increasing dose
16 Therapy With Bromocriptine in Patients With Symptomatic Risperidone-Induced Hyperprolactinemia Unknown status NCT00315081 Phase 3 Bromocriptin
17 Study of Serum Prostatic Specific Antigen (PSA) After Cyproterone Compound Treatment Compared With Oral Contraceptives Pill in Hirsute Polycystic Ovary Syndrome Patients Unknown status NCT00955058 Phase 2, Phase 3 OCP
18 Comparison Between Letrozole and Laparoscopic Ovarian Drilling in Women With Clomiphene Resistant Polycystic Ovarian Syndrome (PCOS) Unknown status NCT02305693 Phase 3 Letrozole
19 Comparison Between Laproscopic Ovarian Diathermy and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome: A Randomised Controlled Trial Unknown status NCT02304536 Phase 3 FSH
20 Counteracting Risperidone-Induced Hyperprolactinemia in Youths Completed NCT00799383 Phase 3 Calcium and Vitamin D
21 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia Completed NCT01668797 Phase 3 Brexpiprazole;Placebo
22 A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia Completed NCT01397786 Phase 3 OPC-34712
23 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Three Fixed Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia Completed NCT01396421 Phase 3 OPC-34712 [Brexpiprazole] High Dose;Experimental: OPC-34712 [Brexpiprazole] Middle Dose;Experimental: OPC-34712 [Brexpiprazole] Low Dose;Placebo
24 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Fixed-dose OPC-34712 in the Treatment of Adults With Acute Schizophrenia Completed NCT01393613 Phase 3 OPC-34712;OPC-34712;OPC-34712;Placebo
25 Efficacy and Safety of Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia or Schizoaffective Disorder With Risperidone as an Active Control Completed NCT00283179 Phase 3 Aripiprazole;Risperidone
26 Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome Completed NCT00427700 Phase 3 clomiphene citrate;raloxifene
27 Study On The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS) Completed NCT01577017 Phase 3 Letrozole
28 Extended Clomiphene Citrate Regimen Versus Laparoscopic Ovarian Drilling for Ovulation Induction in Clomiphene Citrate-resistant Women With Polycystic Ovary Syndrome Completed NCT02381184 Phase 2, Phase 3 clomiphene citrate
29 Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Polycystic Ovary Syndrome Unknown status NCT02551367 Phase 2 Letrozole;Clomiphene citrate;hcg hormone
30 Effect of Non-surgical Periodontal Therapy Along With Myo-inositol on High Sensitivity C-reactive Protein and Insulin Resistance in Polycystic Ovary Syndrome Women Having Chronic Periodontitis: A Randomized Controlled Trial Unknown status NCT02633462 Phase 2 Myo-inositol
31 The Herbal Medicine Peony-Glycyrrhiza Decoction (PGD) as an Adjunctive Therapy to Treat Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia: a Double-blind, Randomized, Placebo-controlled Study Completed NCT01852331 Phase 2 PGD granules;Placebo
32 Compare the Efficacy of Human Albumin With Cabergoline to Prevent of Ovarian Hyper Stimulation in ART Program Completed NCT01009567 Phase 1, Phase 2 Cabergoline;Control
33 An Open-Label Study of Aripiprazole in Children and Adolescents With Autistic Disorder Completed NCT00198055 Phase 2 aripiprazole
34 Phase 2 Study of Recombinant Human Prolactin Efficacy and Safety Completed NCT00438490 Phase 2 Recombinant Human Prolactin
35 Recombinant Human Prolactin for Lactation Induction in Prolactin Deficient Mothers Completed NCT00181623 Phase 2 Recombinant Human Prolactin
36 Comparison of the Effects of Monotherapy With Exenatide or Metformin to Combined Exenatide and Metformin Therapy on Menstrual Cyclicity in Overweight Women With Polycystic Ovary Syndrome Completed NCT00344851 Phase 2 metformin, exenatide or combined (metformin & exenatide )
37 Recombinant Human Prolactin for Lactation Induction in Mothers of Premature Infants Completed NCT00181610 Phase 2 Recombinant Human Prolactin
38 Administration of Kisspeptin in Patients With Hyperprolactinemia Recruiting NCT02956447 Phase 2 Kisspeptin 112-121;Gonadotropin Releasing Hormone (GnRH)
39 Comparison of Metformin and Pioglitazone in Regulating Menstrual Irregularities and Hyperandrogenism Recruiting NCT03757923 Phase 1, Phase 2 TAB METFORMIN;TAB PIOGLITAZONE
40 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability Active, not recruiting NCT03038308 Phase 1, Phase 2 Ropinirole
41 Effectiveness and Safety of Bushen Culuan Decoction for Anovulatory Infertility:A Clinical Research of "Same Treatment for Different Diseases" Not yet recruiting NCT03709849 Phase 2 experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo;control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo
42 Exploratory Phase 2 Study of Farletuzumab in Resectable Non-functioning Pituitary Adenoma Withdrawn NCT01203618 Phase 2 Farletuzumab
43 Recombinant Human Prolactin for Lactation Induction in Adoptive Mothers Withdrawn NCT00181649 Phase 2 Recombinant human prolactin
44 Luteal Phase Versus Follicular Phase Administration of Clomiphene Citrate in PCOS, A Randomized Controlled Trial Unknown status NCT02024984 Phase 1 Clomiphene Citrate
45 Reducing Antipsychotic-Induced Weight Gain in Children With Metformin Completed NCT01231074 Phase 1 Metformin
46 Nurse's Role in the Management of Hyperprolactinemia: A Prospective Randomized Controlled Trial Recruiting NCT04262024 Phase 1 Cabergoline 0.5Mg orally daily for 1 month plus health education by a nurse;Cabergoline 0.5Mg orally daily for 1 month without health education by a nurse
47 Kisspeptin Administration in the Adult Recruiting NCT00914823 Phase 1 kisspeptin 112-121;GnRH
48 A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma Terminated NCT02629549 Phase 1 OTL38
49 Prognostic Value of Pituitary Histopathology and Plasma Hyperprolactinaemia in Predicting the Risk of Glucose Metabolic Disturbances in Patients With Acromegaly. Unknown status NCT02092129
50 Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study Unknown status NCT02013232 Aripiprazole

Search NIH Clinical Center for Hyperprolactinemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


2-Bromoergocryptine Mesylate
Bromocriptine
cabergoline

Cochrane evidence based reviews: hyperprolactinemia

Genetic Tests for Hyperprolactinemia

Genetic tests related to Hyperprolactinemia:

# Genetic test Affiliating Genes
1 Hyperprolactinemia 29 PRLR

Anatomical Context for Hyperprolactinemia

MalaCards organs/tissues related to Hyperprolactinemia:

40
Pituitary, Ovary, Bone, Breast, Testes, Prostate, Thyroid

Publications for Hyperprolactinemia

Articles related to Hyperprolactinemia:

(show top 50) (show all 4924)
# Title Authors PMID Year
1
Variant Prolactin Receptor in Agalactia and Hyperprolactinemia. 61 6 56
30575453 2018
2
Mutant prolactin receptor and familial hyperprolactinemia. 56 61
24597877 2014
3
Mutant prolactin receptor and familial hyperprolactinemia. 61 56
24597878 2014
4
Mutant prolactin receptor and familial hyperprolactinemia. 61 56
24597879 2014
5
Mutant prolactin receptor and familial hyperprolactinemia. 61 56
24597880 2014
6
Mutant prolactin receptor and familial hyperprolactinemia. 56 61
24195502 2013
7
Lack of expression of endometrial prolactin in early implantation failure: a pilot study. 56
15218000 2004
8
Hyperprolactinemia associated with psychotropics--a review. 61 54
20521318 2010
9
Comparison of multiple methods for identification of hyperprolactinemia in the presence of macroprolactin. 61 54
19895797 2010
10
Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients. 54 61
19896213 2010
11
HER2 expression in breast cancer: correlation with endocrine function and psychological status in operable and metastatic breast cancer. 61 54
20023245 2009
12
Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. 54 61
19451414 2009
13
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. 61 54
19339912 2009
14
Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. 54 61
19158203 2009
15
Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia. 61 54
19059524 2009
16
Primary hypothyroidism in a child simulating a prolactin-secreting adenoma. 61 54
18690463 2008
17
Endocrine manifestations of the rapid-onset obesity with hypoventilation, hypothalamic, autonomic dysregulation, and neural tumor syndrome in childhood. 61 54
18628522 2008
18
Current guidelines and their recommendations for prolactin monitoring in psychosis. 61 54
18477625 2008
19
[Biochemical aspects of modified, transdermal replacement hormone therapy]. 54 61
18411913 2007
20
Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice. 54 61
17848635 2007
21
Pharmacological causes of hyperprolactinemia. 54 61
18473017 2007
22
Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia. 61 54
17557033 2007
23
Polycystic ovary syndrome and hyperprolactinemia are distinct entities. 61 54
17558684 2007
24
Development of anti-PRL (prolactin) autoantibodies by homologous PRL in rats: a model for macroprolactinemia. 61 54
17303669 2007
25
Hyperprolactinemia and immunohistochemical expression of intracellular prolactin and prolactin receptor in primary central nervous system tumors and their relationship with cellular replication. 61 54
18095129 2007
26
Atypical antipsychotics and pituitary neoplasms in the WHO database. 54 61
17285098 2007
27
[Hyperprolactinemia: causes, diagnosis, and treatment]. 54 61
17253440 2006
28
Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? 61 54
17024156 2006
29
Clinical and biochemical characteristics of a male patient with a novel homozygous STAT5b mutation. 61 54
16787985 2006
30
Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. 61 54
16554049 2006
31
Gene therapy in the neuroendocrine system. 54 61
16809929 2006
32
Prolactin suppresses GnRH but not TSH secretion. 61 54
16357488 2006
33
Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. 61 54
16144946 2005
34
The dopamine receptor D2 genotype is associated with hyperprolactinemia. 61 54
16169407 2005
35
Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer. 61 54
16011043 2005
36
Symptomatic Rathke's cleft cysts: a report of 24 cases. 61 54
15762042 2004
37
Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. 61 54
15554761 2004
38
The hypothalamic-pituitary axis in men and women with chronic kidney disease. 61 54
15492969 2004
39
Gender differences in systemic lupus erythematosus. 54 61
16115579 2004
40
Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors. 61 54
15638294 2004
41
[Treatment of acne with antiandrogens--an evidence-based review]. 54 61
16295039 2003
42
Macroprolactinemia: a new cause of hyperprolactinemia. 61 54
12890882 2003
43
[Pharmacokinetic/pharmacodynamic analysis of anti-hyperprolactinemic effect of terguride based on dopamine D2 receptor occupancy]. 61 54
12704865 2003
44
Antifertility effects of fluphenazine in adult male rats. 61 54
12841539 2003
45
Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. 61 54
12650682 2003
46
Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: possible usefulness of the domperidone test. 61 54
12713252 2003
47
An evaluation of patients with hyperprolactinemia: have dynamic tests had their day? 61 54
14604065 2003
48
[Hirsutism and hypertrichosis in adults: investigations and treatment]. 61 54
12223963 2002
49
Effect of transitory hyperprolactinemia on in vitro fertilization of human oocytes. 61 54
11396370 2001
50
Basal, pulsatile, entropic, and 24-hour rhythmic features of secondary hyperprolactinemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinemia. 61 54
11297584 2001

Variations for Hyperprolactinemia

ClinVar genetic disease variations for Hyperprolactinemia:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PRLR NM_000949.7(PRLR):c.511C>T (p.Arg171Ter)SNV Pathogenic 599315 rs376188691 5:35072709-35072709 5:35072607-35072607
2 PRLR NM_000949.7(PRLR):c.806C>T (p.Pro269Leu)SNV Pathogenic 599316 rs754974807 5:35068367-35068367 5:35068265-35068265
3 PRLR NM_000949.7(PRLR):c.635A>G (p.His212Arg)SNV Pathogenic 89027 rs398122522 5:35070276-35070276 5:35070174-35070174

UniProtKB/Swiss-Prot genetic disease variations for Hyperprolactinemia:

73
# Symbol AA change Variation ID SNP ID
1 PRLR p.His212Arg VAR_070895 rs398122522

Expression for Hyperprolactinemia

Search GEO for disease gene expression data for Hyperprolactinemia.

Pathways for Hyperprolactinemia

Pathways related to Hyperprolactinemia according to KEGG:

36
# Name Kegg Source Accession
1 PI3K-Akt signaling pathway hsa04151
2 JAK-STAT signaling pathway hsa04630
3 Prolactin signaling pathway hsa04917

Pathways related to Hyperprolactinemia according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 VIP TRH SST PTHLH POMC INS
2
Show member pathways
13.44 PRLR PRL INS IGF1 GNRH1 GNAS
3
Show member pathways
13.23 IGF1 HTR2C HTR2A GNRH1 GNAS GHRH
4
Show member pathways
12.94 INS IGF1 GNRH1 GNAS GHRH GH1
5
Show member pathways
12.88 PRLR PRL INS IGF1 GNAS GH1
6
Show member pathways
12.85 POMC HTR2C HTR2A GNAS GHRH GH1
7
Show member pathways
12.81 VIP TRH SST PTHLH PRLR PRL
8
Show member pathways
12.51 IGF1 HTR2C HTR2A GNRH1 GNAS
9
Show member pathways
12.39 SST POMC IGF1 GNAS GHRH GH1
10
Show member pathways
12.37 PRLR PRL INS GH1
11
Show member pathways
12.14 POMC INS IGF1 GH1
12 12.1 VIP SST POMC GNAS DRD2
13 11.92 PRLR INS IGF1 GH1
14
Show member pathways
11.82 HTR2C HTR2A DRD4 DRD2
15 11.72 VIP PTHLH POMC GNAS GHRH
16 11.65 HTR2C HTR2A GNAS DRD2
17 11.6 IGF1 GNRH1 GNAS GHRH GH1
18 11.58 PTHLH IGF1 GH1
19 11.44 INS IGF1 GNAS
20 11.42 PRLR PRL INS
21
Show member pathways
11.33 PRLR PRL GH1
22 11.08 HTR2C HTR2A GNAS
23 10.91 IGF1 GNRH1 GNAS GHRH GH1
24 10.65 PRL POMC INS HTR2C DRD2

GO Terms for Hyperprolactinemia

Cellular components related to Hyperprolactinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.85 SST PTHLH PRL POMC INS IGF1
2 dendrite GO:0030425 9.73 HTR2C HTR2A GNRH1 GNAS DRD4 DRD2
3 perikaryon GO:0043204 9.62 VIP GNRH1 GHRH DRD2
4 extracellular region GO:0005576 9.5 VIP TRH SST SHBG PTHLH PRLR
5 endosome lumen GO:0031904 9.26 PRLR PRL INS GH1

Biological processes related to Hyperprolactinemia according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 10.01 SST PTHLH GNRH1 GAL DRD2
2 signal transduction GO:0007165 10 VIP TRH PTHLH PRL POMC INS
3 chemical synaptic transmission GO:0007268 9.94 SST HTR2C HTR2A DRD4
4 positive regulation of cell proliferation GO:0008284 9.86 VIP PTHLH PRLR PRL INS IGF1
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.83 IGF1 HTR2A GH1
6 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.83 VIP PTHLH GNAS GHRH
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.82 INS IGF1 GH1
8 response to drug GO:0042493 9.8 SST HTR2C HTR2A GNAS GAL DRD2
9 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.78 HTR2C HTR2A DRD4
10 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.77 VIP HTR2C HTR2A
11 release of sequestered calcium ion into cytosol GO:0051209 9.76 HTR2C HTR2A DRD2
12 female pregnancy GO:0007565 9.76 PTHLH PRL GNRH1 GNAS
13 feeding behavior GO:0007631 9.74 HTR2C GAL DRD2
14 positive regulation of multicellular organism growth GO:0040018 9.73 GHRH GH1 DRD2
15 negative regulation of protein secretion GO:0050709 9.67 INS DRD4 DRD2
16 positive regulation of glycolytic process GO:0045821 9.65 INS IGF1 HTR2A
17 positive regulation of growth hormone secretion GO:0060124 9.64 GHRH DRD2
18 negative regulation of potassium ion transport GO:0043267 9.63 VIP HTR2A
19 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.63 DRD4 DRD2
20 adenohypophysis development GO:0021984 9.62 GHRH DRD2
21 serotonin receptor signaling pathway GO:0007210 9.62 HTR2C HTR2A
22 behavioral response to cocaine GO:0048148 9.61 HTR2A DRD4 DRD2
23 regulation of appetite GO:0032098 9.59 POMC HTR2C
24 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.58 HTR2C HTR2A
25 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.58 PRLR PRL GH1
26 cell-cell signaling GO:0007267 9.56 TRH SST PTHLH POMC INS GNRH1
27 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.55 DRD4 DRD2
28 response to histamine GO:0034776 9.54 DRD4 DRD2
29 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.54 IGF1 GHRH GH1
30 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.51 HTR2C HTR2A
31 G protein-coupled receptor signaling pathway GO:0007186 9.47 VIP TRH SST PTHLH POMC INS

Molecular functions related to Hyperprolactinemia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.67 HTR2C HTR2A DRD4
2 G protein-coupled serotonin receptor activity GO:0004993 9.61 HTR2C HTR2A DRD4
3 neuropeptide hormone activity GO:0005184 9.58 VIP GHRH GAL
4 drug binding GO:0008144 9.56 HTR2C HTR2A DRD4 DRD2
5 dopamine binding GO:0035240 9.52 DRD4 DRD2
6 serotonin binding GO:0051378 9.51 HTR2C HTR2A
7 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.48 DRD4 DRD2
8 dopamine neurotransmitter receptor activity GO:0004952 9.46 DRD4 DRD2
9 hormone activity GO:0005179 9.4 VIP TRH SST PTHLH PRL POMC
10 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.37 HTR2C HTR2A
11 insulin-like growth factor receptor binding GO:0005159 9.33 INS IGF1 GNAS
12 prolactin receptor binding GO:0005148 9.32 PRL GH1
13 peptide hormone receptor binding GO:0051428 9.13 VIP PTHLH GHRH

Sources for Hyperprolactinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....